Medicare Enrolled

Dr. Carl Chakmakjian, D.O.

Medical Oncology · Waco, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
1700 W HIGHWAY 6, Waco, TX 76712
2543990741
In practice since 2006 (19 years)
NPI: 1285675306 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Chakmakjian from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Chakmakjian? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Chakmakjian

Dr. Carl Chakmakjian is a medical oncology in Waco, TX, with 19 years in practice. Based on federal Medicare data, Dr. Chakmakjian performed 49,473 Medicare services across 2,253 unique beneficiaries.

Between the years covered by Open Payments, Dr. Chakmakjian received a total of $284,069 from 45 pharmaceutical and/or device companies across 314 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Chakmakjian is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 20% volume in TX$ $284,069 industry payments

Medicare Practice Summary

Medicare Utilization ↗
49,473
Medicare services
Top 20% in TX for medical oncology
2,253
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,604 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Iron infusion (Feraheme)15,300$0$5
Darbepoetin injection (Aranesp) for anemia8,290$2$20
Contrast dye for imaging (iodine-based)6,517$0$3
Anti-nausea injection (fosaprepitant)5,100$0$5
Paclitaxel chemotherapy injection3,438$0$8
Dexamethasone injection (steroid)2,995$0$1
Injection, granisetron hydrochloride, 100 mcg1,020$0$24
Blood draw (venipuncture)1,006$8$20
Office visit, established patient (30-39 min)834$89$368
Complete blood count (CBC) with differential786$8$36
Anti-nausea injection (Aloxi/palonosetron)640$1$114
Injection of additional new drug or substance into vein374$11$108
Administration of chemotherapy into vein, 1 hour or less318$94$707
Injection, carboplatin, 50 mg270$2$300
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less233$20$157
Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session231$272$2,762
Office visit, established patient (20-29 min)209$62$250
Microscopic examination for white blood cells with manual cell count173$4$22
Complete blood count (CBC), automated173$6$34
Infusion into a vein for hydration, each additional hour163$9$75
Infusion, normal saline solution , 1000 cc136$2$19
Injection, zoledronic acid, 1 mg112$6$431
Drug injection, under skin or into muscle100$10$96
Injection, diphenhydramine hcl, up to 50 mg98$1$7
Reticulated (young) platelet measurement93$35$143
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less92$45$313
Administration of additional new drug or substance into vein, 1 hour or less84$49$344
Ct scan of chest with contrast74$43$821
Administration of chemotherapy into vein, each additional hour70$18$161
CT scan of abdomen and pelvis with contrast68$169$1,067
New patient office visit (45-59 min)67$121$565
Unclassified drugs63$1$8
Irrigation of implanted venous access drug delivery device44$18$114
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour40$16$100
Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev39$178$700
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg38$348$1,722
CT scan of chest, without contrast36$35$686
Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev34$177$700
Ct scan of abdomen and pelvis without contrast30$77$560
Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle26$26$145
Hospital follow-up visit, moderate complexity23$58$247
Nuclear medicine study from skull base to mid-thigh with ct scan21$1,092$4,802
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries15$91$657
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
32.3% high complexity
60.0% medium
7.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$284,069
Total received (2018-2024)
Avg $40,581/year across 7 years
Top 7% in TX for medical oncology
45
Companies
314
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$277,243 (97.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$4,379 (1.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,447 (0.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$24,851
2023
$17,950
2022
$40,858
2021
$40,601
2020
$16,737
2019
$74,822
2018
$68,249

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$277,011
Novartis Pharmaceuticals Corporation
$3,991
Celgene Corporation
$654
Janssen Biotech, Inc.
$238
Incyte Corporation
$183
Merck Sharp & Dohme LLC
$182
AstraZeneca Pharmaceuticals LP
$166
Astellas Pharma US Inc
$115
Regeneron Healthcare Solutions, Inc.
$111
Merck Sharp & Dohme Corporation
$108
Janssen Scientific Affairs, LLC
$103
Dendreon Pharmaceuticals LLC
$102
Taiho Oncology, Inc.
$98
Daiichi Sankyo Inc.
$80
Eisai Inc.
$77
GENZYME CORPORATION
$59
GlaxoSmithKline, LLC.
$56
Bayer Healthcare Pharmaceuticals Inc.
$53
Lilly USA, LLC
$50
PFIZER INC.
$50
PharmaEssentia USA Corporation
$48
Takeda Pharmaceuticals U.S.A., Inc.
$46
Ipsen Biopharmaceuticals, Inc
$40
Mirati Therapeutics, Inc.
$33
Gilead Sciences, Inc.
$32
Seagen Inc.
$32
ADC Therapeutics America, Inc.
$28
Karyopharm Therapeutics Inc.
$26
Sirtex Medical Inc
$23
Genmab U.S., Inc.
$22
Puma Biotechnology, Inc.
$21
TAIHO ONCOLOGY, INC.
$20
EMD Serono, Inc.
$20
Adaptive Biotechnologies Corporation
$19
Amgen Inc.
$19
Stemline Therapeutics Inc.
$18
PUMA BIOTECHNOLOGY, INC.
$18
SOBI, INC
$16
BeiGene USA, Inc.
$16
Bayer HealthCare Pharmaceuticals Inc.
$16
Tempus AI, Inc
$15
MENARINI SILICON BIOSYSTEMS, INC.
$15
Ironshore Pharmaceuticals Inc.
$14
Boston Scientific Corporation
$14
Myriad Genetic Laboratories, Inc.
$12
Top 3 companies account for 99.2% of total payments
Associated products mentioned in payments ›
ADCETRIS · AUGTYRO · BARACLUDE · BAVENCIO · BESREMI · BLENREP · BRUKINSA · CABLIVI · CALQUENCE · Cellsearch · DARZALEX · ELIQUIS · ELREXFIO · EMPLICITI · ENHERTU · Enhertu · Epkinly · Fabhalta · IBRANCE · IMBRUVICA · IMFINZI · JAKAFI · JEMPERLI · JORNAY PM · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LONSURF · LUMAKRAS · Lenvima · Lonsurf · MEKINIST · MONJUVI · NINLARO · Nubeqa · OJJAARA · OPDIVO · Orserdu · PADCEV · PIQRAY · PROMACTA · PROVENGE · REBLOZYL · RETEVMO · SARCLISA · SIR-Spheres Microspheres · SOMATULINE DEPOT · SpaceOAR VUE System - 10mL · Stivarga · TASIGNA · TECVAYLI · VERZENIO · VONJO · XPOVIO · Xofigo · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (98%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 7% for medical oncology in TX.

Equivalent to $574 per 100 Medicare services performed
Looking for a medical oncology in Waco?
Compare medical oncologys in the Waco area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
5
Per 100K population
1.9
County median income
$63,888
Nearest hospital
ASCENSION PROVIDENCE
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Chakmakjian is a mixed practice specialist, with above-average Medicare volume (top 20% in TX), and high industry engagement (speaking/promotional, top 7%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Chakmakjian experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Chakmakjian performed 15,300 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Chakmakjian receive payments from pharmaceutical companies?
Yes. Dr. Chakmakjian received a total of $284,069 from 45 companies across 314 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Chakmakjian's costs compare to other medical oncologys in Waco?
Dr. Chakmakjian's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Chakmakjian) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →